Senseye

The company addresses the subjectivity and inaccuracy of current mental health assessments, which rely heavily on self-reporting, as well as the lack of objective diagnostic tools that lead to misdiagnosis and long wait times for patients.

The company utilizes fully patented approaches to deep learning and signal extraction that allow for the analysis of the autonomic nervous system via the eyes using standard smartphone hardware.

The company notes that 6% of the population will experience PTSD at some point in their lives, with 19 million cases in the U.S. and 465 million worldwide.

Senseye is the first ocular diagnostic tool for mental health

Senseye is building what it positions as the first objective, smartphone-based diagnostic for mental health, starting with PTSD: a roughly 10-minute ocular test that uses computer vision and patented machine learning to read autonomic signals in the eyes rather than self-reports or long clinical interviews. The company is now in a large Phase 3 trial (REVEAL) aimed at an FDA De Novo submission in late 2026, with protocols already reviewed by the FDA, and it claims a growing clinical dataset of more than 300,000 recorded sessions that can be re-analyzed as models improve. That data, plus nine issued patents and about 20 more filings, a planned reimbursement path (~$90 for the initial test and ~$50 for monitoring visits), and operators with Teladoc and FDA device-review backgrounds, is what makes the platform hard to copy and commercially relevant if approval comes through. In short, Senseye is special because it turns an ordinary phone camera into a scalable, brain-based measurement tool for conditions that have historically depended on subjective interviews.